Schizophrenia and schizoaffective disorders are severe mental conditions characterized by hallucinations, delusions, and mood disturbances. The Journal of Clinical Psychiatry offers a deep dive into these disorders, emphasizing their diagnosis, management, and underlying causes. Our expert editors ensure content is both clinically relevant and actionable, aiding psychiatrists in offering effective and compassionate care.
Schizophrenia and Schizoaffective Disorders
Page 7
Recently published articles about Schizophrenia/Schizoaffective Disorders
Original Research
Safety and Tolerability of Initiating With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months
February 28, 2024
In this post hoc analysis, treatment of acutely exacerbated schizophrenia with aripiprazole lauroxil or paliperidone palmitate was well tolerated, consistent with the safety profiles of these medications.
Original Research
Effect of Lurasidone on Social Functioning
January 31, 2024
Impaired social functioning in schizophrenia affects personal recovery. This analysis looked at the effects of lurasidone on social functioning in schizophrenia during a double-blind, placebo-controlled study and subsequent open-label...
Narrative Review
Alternative Treatment for Agitation in Schizophrenia and Bipolar Disorder
January 30, 2024
While oral and intramuscular formulations of pharmacologic agents continue to be commonly used to treat acute agitation, novel agents with alternative routes of delivery are becoming available.
Systematic Review
Cognition in Schizophrenia
October 12, 2023
This systematic review showed specific cognitive functioning in individuals diagnosed with schizophrenia, highlighting lower than average performance compared to healthy controls regarding executive cognitive functions such as information processing,...
Original Research
Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia
September 25, 2023
Long-acting injectable antipsychotics (LAIs) are typically reserved for patients with a long history of schizophrenia. This analysis of 3 studies found benefit in initiating the LAI paliperidone palmitate earlier...
Original Research
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg
September 4, 2023
A new formulation of injectable aripiprazole for administration every 2 months showed similar rates of treatment-emergent adverse events to aripiprazole once-monthly 400 mg. Patients in both groups remained clinically...
